📊

Executive Summary

Preclinical once-monthly TransCon semaglutide prodrug for obesity and diabetes, developed in exclusive global partnership with Novo Nordisk

TransCon_semaglutide

· TransCon prodrug

Preclinical

Target:

Mechanism of Action

Target Biology

No target biology data available.

Clinical Data

No clinical trial data available.

Market Opportunity

Partner

Novo Nordisk

Catalysts & Upcoming Events

No catalyst data available.

Data sourced exclusively from public filings, corporate presentations, and published clinical data. For informational purposes only. Not investment advice. Satya Bio does not provide recommendations to buy or sell securities. Terms · Privacy